Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in <i>PIK3CA</i> - and <i>HRAS</i> -dysregulated HNSCC via convergent inhibition of mTOR activity
Alison Smith(Memorial Sloan Kettering Cancer Center), Shivani Malik(Salk Institute for Biological Studies)
Cited by 0
Related Papers
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
|Nature Communications|2021|86
SMARCA4 supports the oncogenic landscape of <i>KRAS</i> -driven lung tumors
|bioRxiv (Cold Spring Harbor Laboratory)|2020|4